Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Safety and effectiveness of 100 mg/kg/day deferiprone in patients with thalassemia major: A two-year study
Acta Haematologica, Volume 114, No. 3, Year 2005
Notification
URL copied to clipboard!
Description
Deferiprone at a dose of 75 mg/kg/day is not sufficiently effective to maintain iron stores at a level which has been considered safe in all patients with iron overload. Our main aim was to determine the safety of long-term therapy with high-dose (100 mg/kg/day) deferiprone. A secondary aim was to determine the efficacy of this high dose. Twelve thalassemia major patients received deferiprone at a dose of 100 mg/kg/day over 2 years. Transient aspartate aminotransferase increase (8 patients), gastrointestinal discomfort (3 patients) and arthralgia (2 patients) were the most commonly reported side effects. None of the patients discontinued therapy. The mean serum ferritin level fell from 3,901 ± 3,618 to 1,790 ± 2,205 μg/l after 2 years (p < 0.05). Five of the 12 patients continued to receive deferiprone for an additional 3 years. No new side effects were encountered. The mean serum ferritin level in this subgroup was initially 2,510 ± 332 μg/l and dropped to 1,511 ± 664 μg/l after 5 years (p < 0.05). Liver iron levels at the end of the 2-year study ranged from 1.0 to 30.9 mg/g dry weight, 3 of the patients having levels above 15 mg/g. Copyright © 2005 S. Karger AG.
Authors & Co-Authors
Taher, Ali T.
Lebanon, Beirut
American University of Beirut Medical Center
Lebanon, Hazmieh
Chronic Care Center, Hazmieh
Sheikh-Taha, Marwan T.
Lebanon, Beirut
Lebanese American University
Sharara, Ala I.
Lebanon, Beirut
American University of Beirut Medical Center
Inati, Adlette
Lebanon, Hazmieh
Chronic Care Center, Hazmieh
Koussa, Suzanne C.
Lebanon, Hazmieh
Chronic Care Center, Hazmieh
Ellis, Gareth
United Kingdom, London
Ucl Medical School
Dhillon, A. P.
United Kingdom, London
Ucl Medical School
Hoffbrand, Allan Victor
United Kingdom, London
Ucl Medical School
Statistics
Citations: 38
Authors: 8
Affiliations: 4
Identifiers
Doi:
10.1159/000087888
ISSN:
00015792